Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, announces that the Food and Drug Administration has issued its Guidance Document to support the classification of the Company's BIOGUARD™ barrier gauze wound dressings as Class II medical devices. The newly issued guidance pertains to a wound dressing with permanently bound cationic biocide polyDADMAC, one of the molecular entities covered in nine Quick-Med U.S. patents/patents pending and in 24 foreign counterparts.
According to the company, BIOGUARD dressings feature:
- The technology subject of the newly issued Guidance.
- The ability for the dressings to serve as a barrier to infection, kill germs absorbed into the dressing and provide an optimum wound healing environment.
- An active agent that maintains effectiveness even in the presence of large amounts of wound fluid.
- A non-leaching antimicrobial wound dressing, while other antimicrobial dressings rely on the release of chemicals to the wound bed, could cause the formation of resistant bacterial strains.
- Ideal use as prophylactic infection control dressings, especially in the hospital environment, where deaths related to hospital-acquired infections have risen to become the fourth leading cause of death in the U.S. after heart disease, automobile accidents and cancer.
For more information, visit www.dermasciences.com